Special Issue

Antimicrobial Resistance, Epidemiology, Clinical Impact and Molecular Characterization of Multidrug-Resistant ESKAPEE Pathogens

Message from the Guest Editors

The acronym ESKAPEE identifies bacteria (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp. and Escherichia coll) that are able to escape the biocidal action of antimicrobials, presenting high rates of multi-resistance. Available treatment options are increasingly ineffective against these pathogens, which may lead to a future in which antibiotics are ineffective. In the food sector, ESKAPEE pathogens can pose a threat to public health. The overuse or misuse of antibiotics in animal husbandry could increase their resistance, thus promoting their spread throughout food production and consumption. This Special Issue is seeking manuscripts that advance our understanding of various aspects of ESKAPEE pathogens, specifically: Mechanisms of antimicrobial resistance Phenotypic and genotypic assessment of antibiotic resistance

Molecular characterization of multidrug-resistant ESKAPEE pathogens

Nosocomial outbreaks caused by ESKAPEE pathogens Identification of ESKAPEE pathogens in food and environmental samples

Novel drug combinations designed to combat infections caused by ESKAPEE pathogens

Guest Editors

Dr. Lorenzo Pace

Istituto Zooprofilattico Sperimentale of Puglia and Basilicata, Anthrax Reference Institute of Italy, 71121 Foggia, Italy

Dr. Viviana Manzulli

Istituto Zooprofilattico Sperimentale della Puglia e della Basilicata, 71121 Foggia, Italy

Deadline for manuscript submissions

30 April 2026



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/234413

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

